Combining Notch inhibition with current therapies for breast cancer treatment

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 1, 2013, Pages 17-24

  Brennan, Keith ^a   Clarke, Robert B ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

breast cancer; combination therapy; Notch; Notch inhibitors

Indexed keywords

ADAM10 ENDOPEPTIDASE; CYCLIN A; CYCLIN B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA SECRETASE INHIBITOR; JAGGED1; NOTCH PATHWAY INHIBITOR; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL RENEWAL; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; INTRACELLULAR SIGNALING; INTRADUCTAL CARCINOMA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84877881712     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012457437     Document Type: Review

References (70)

1. Andersson E. Sandberg R. Lendahl U. (2011) Notch signaling: simplicity in design, versatility in function. Development 138: 3593–3612.
2. Arcaroli J. Dasari A. Messersmith W. Jimeno A. (2011) γ-Secretase inhibitors in solid tumor malignancies. Drugs Fut 36: 677–690.
3. Arnett K. Hass M. McArthur D. Ilagan M. Aster J. Kopan R. et al. (2010) Structural and mechanistic insights into cooperative assembly of dimeric Notch transcription complexes. Nat Struct Mol Biol 17: 1312–1317.
4. Aste-Amezaga M. Zhang N. Lineberger J. Arnold B. Toner T. Gu M. et al. (2010) Characterization of Notch 1 antibodies that inhibit signaling of both normal and mutated Notch 1 receptors. PloS ONE 5 (2): e9094.
5. Aveo Pharmaceuticals, I. Notch Program. Available at: http://www.aveopharma.com/discovery_programs/notch_program/.
6. Bernard F. Krejci A. Housden B. Adryan B. Bray S. (2010) Specificity of Notch pathway activation: twist controls the transcriptional output in adult muscle progenitors. Development 137: 2633–2642.
7. Bolos V. Grego-Bessa J. de la Pompa J. (2007) Notch signaling in development and cancer. Endocr Rev 28: 339–363.
8. Bouras T. Pal B. Vaillant F. Harburg G. Asselin-Labat M. Oakes S. et al. (2008) Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3: 429–441.
9. Bray S. (2006) Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 7: 678–689.
10. Carey L. Winer E. Viale G. Cameron D. Gianni L. (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7: 683–692.
11. Cho S. Lu M. He X. Ee P. Bhat U. Schneider E. et al. (2011) Notch 1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A 108: 20778–20783.
12. Cook N. Frese K. Bapiro T. Jacobetz M. Gopinathan A. Miller J. et al. (2012) Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 209: 437–444.
13. Dong Y. Li A. Wang J. Weber J. Michel L. (2010) Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70: 5465–5474.
14. Dufraine J. Funahashi Y. Kitajewski J. (2008) Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 27: 5132–5137.
15. Epenetos A. Kosparou C. Stylianou S. (2009) Inhibition of Notch signaling for the treatment of human carcinomas. In: Proceedings of the American Assocication of Cancer Research, 18–22 April, Denver, CO.
16. Farnie G. Clarke R. Spence K. Pinnock N. Brennan K. Anderson N. et al. (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 99: 616–627.
17. Fischer A. Gessler M. (2007) Delta-Notch–and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res 35: 4583–4596.
18. Han J. Ma I. Hendzel M. Allalunis-Turner J. (2009) The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res 11 (4): R57.
19. Harrison H. Farnie G. Howell S. Rock R. Stylianou S. Brennan K. et al. (2010) Regulation of breast cancer stem cell activity by signaling through the Notch 4 receptor. Cancer Res 70: 709–718.
20. Haughian J. Pinto M. Harrell J. Bliesner B. Joensuu K. Dye W. et al. (2011) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 109: 2742–2747.
21. He W. Luistro L. Carvajal D. Smith M. Nevins T. Yin X. et al. (2011) High tumor levels of IL 6 and IL 8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097. Mol Oncol 5: 292–301.
22. Hoey T. Yen W. Axelrod F. Basi J. Donigian L. Dylla S. et al. (2009) DLL 4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5: 168–177.
23. Kondratyev M. Kreso A. Hallett R. Girgis-Gabardo A. Barcelon M. Ilieva D. et al. (2012) Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB 2 breast cancer. Oncogene 31: 93–103.
24. Lee C. Raskett C. Prudovsky I. Altieri D. (2008 a) Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 68: 5273–5281.
25. Lee C. Simin K. Liu Q. Plescia J. Guha M. Khan A. et al. (2008 b) A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 10 (6): R97.
26. Leong K. Niessen K. Kulic I. Raouf A. Eaves C. Pollet I. et al. (2007) Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 204: 2935–2948.
27. Li K. Li Y. Wu W. Gordon W. Chang D. Lu M. et al. (2008) Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 283: 8046–8054.
28. Li Y. Burns J. Cheney C. Zhang N. Vitelli S. Wang F. et al. (2010) Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies. Biologics 4: 163–171.
29. Lim E. Vaillant F. Wu D. Forrest N. Pal B. Hart A. et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA 1 mutation carriers. Nat Med 15: 907–913.
30. Liu S. Wicha M. (2010) Targeting breast cancer stem cells. J Clin Oncol 28: 4006–4012.
31. Liu Z. Turkoz A. Jackson E. Corbo J. Engelbach J. Garbow J. et al. (2011) Notch 1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 121: 800–808.
32. Lowell S. Jones P. Le Roux I. Dunne J. Watt F. (2000) Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr Biol 10: 491–500.
33. Mazzone M. Selfors L. Albeck J. Overholtzer M. Sale S. Carroll D. et al. (2010) Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 107: 5012–5017.
34. Meurette O. Stylianou S. Rock R. Collu G. Gilmore A. Brennan K. (2009) Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 69: 5015–5022.
35. Mittal S. Subramanyam D. Dey D. Kumar R. Rangarajan A. (2009) Cooperation of Notch and Ras / MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 8: 128.
36. Moellering R. Cornejo M. Davis T. Del Bianco C. Aster J. Blacklow S. et al. (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462: 182–188.
37. Mumm J. Schroeter E. Saxena M. Griesemer A. Tian X. Pan D. et al. (2000) A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 5: 197–206.
38. Musse A. Meloty-Kapella L. Weinmaster G. (2012) Notch ligand endocytosis: Mechanistic basis of signaling activity. Semin Cell Dev Biol, in press.
39. O'Neill C. Urs S. Cinelli C. Lincoln A. Nadeau R. Leon R. et al. (2007) Notch 2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol 171: 1023–1036.
40. Okochi M. Steiner H. Fukumori A. Tanii H. Tomita T. Tanaka T. et al. (2002) Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. EMBO J 21: 5408–5416.
41. Osipo C. Patel P. Rizzo P. Clementz A. Hao L. Golde T. et al. (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27: 5019–5032.
42. Pandya K. Meeke K. Clementz A. Rogowski A. Roberts J. Miele L. et al. (2011) Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 105: 796–806.
43. Pannuti A. Foreman K. Rizzo P. Osipo C. Golde T. Osborne B. et al. (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141–3152.
44. Parks A. Klueg K. Stout J. Muskavitch M. (2000) Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 127: 1373–1385.
45. Parr C. Watkins G. Jiang W. (2004) The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 14: 779–786.
46. Pece S. Serresi M. Santolini E. Capra M. Hulleman E. Galimberti V. et al. (2004) Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215–221.
47. Pellegrinet L. Rodilla V. Liu Z. Chen S. Koch U. Espinosa L. et al. (2011) Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology 140: 1230–1240, e1231–1237.
48. Prat A. Perou C. (2009) Mammary development meets cancer genomics. Nat Med 15: 842–844.
49. Rana N. Haltiwanger R. (2011) Fringe benefits: functional and structural impacts of O-glycosylation on the extracellular domain of Notch receptors. Curr Opin Struct Biol 21: 583–589.
50. Rangarajan A. Talora C. Okuyama R. Nicolas M. Mammucari C. Oh H. et al. (2001) Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 20: 3427–3436.
51. Reedijk M. Odorcic S. Chang L. Zhang H. Miller N. McCready D. et al. (2005) High-level coexpression of JAG 1 and NOTCH 1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530–8537.
52. Reedijk M. Pinnaduwage D. Dickson B. Mulligan A. Zhang H. Bull S. et al. (2008) JAG 1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 111: 439–448.
53. Rizzo P. Miao H. D'Souza G. Osipo C. Song L. Yun J. et al. (2008) Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68: 5226–5235.
54. Robinson D. Kalyana-Sundaram S. Wu Y. Shankar S. Cao X. Ateeq B. et al. (2011) Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 17: 1646–1651.
55. Sahlgren C. Gustafsson M. Jin S. Poellinger L. Lendahl U. (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 105: 6392–6397.
56. Schwanbeck R. Martini S. Bernoth K. Just U. (2011) The Notch signaling pathway: molecular basis of cell context dependency. Eur J Cell Biol 90: 572–581.
57. Stylianou S. Clarke R. Brennan K. (2006) Aberrant activation of notch signaling in human breast cancer. Cancer Res 66: 1517–1525.
58. Timmerman L. Grego-Bessa J. Raya A. Bertran E. Perez-Pomares J. Diez J. et al. (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 18: 99–115.
59. van Es J. van Gijn M. Riccio O. van den Born M. Vooijs M. Begthel H. et al. (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959–963.
60. van Tetering G. van Diest P. Verlaan I. van der Wall E. Kopan R. Vooijs M. (2009) Metalloprotease ADAM 10 is required for Notch 1 site 2 cleavage. J Biol Chem 284: 31018–31027.
61. Watters J. Cheng C. Majumder P. Wang R. Yalavarthi S. Meeske C. et al. (2009) de novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 69: 8949–8957.
62. Wu Y. Cain-Hom C. Choy L. Hagenbeek T. de Leon G. Chen Y. et al. (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052–1057.
63. Yamaguchi N. Oyama T. Ito E. Satoh H. Azuma S. Hayashi M. et al. (2008) NOTCH 3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 68: 1881–1888.
64. Yan M. Callahan C. Beyer J. Allamneni K. Zhang G. Ridgway J. et al. (2010) Chronic DLL 4 blockade induces vascular neoplasms. Nature 463: E6–E7.
65. Yang L. Nichols J. Yao C. Manilay J. Robey E. Weinmaster G. (2005) Fringe glycosyltransferases differentially modulate Notch 1 proteolysis induced by Delta 1 and Jagged1. Mol Biol Cell 16: 927–942.
66. Yao K. Rizzo P. Rajan P. Albain K. Rychlik K. Shah S. et al. (2011) Notch-1 and notch-4 receptors as prognostic markers in breast cancer. Int J Surg Pathol 19: 607–613.
67. Zang S. Chen F. Dai J. Guo D. Tse W. Qu X. et al. (2010) RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol Rep 23: 893–899.
68. Zardawi S. Zardawi I. McNeil C. Millar E. McLeod D. Morey A. et al. (2010) High Notch 1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology 56: 286–296.
69. Zavadil J. Cermak L. Soto-Nieves N. Bottinger E. (2004) Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23: 1155–1165.
70. Zeng Q. Li S. Chepeha D. Giordano T. Li J. Zhang H. et al. (2005) Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8: 13–23.